TY - JOUR
T1 - Predictive value of the IL28B polymorphism on the effect of interferon therapy in chronic hepatitis C patients with genotypes 2a and 2b
AU - Kawaoka, Tomokazu
AU - Hayes, C. Nelson
AU - Ohishi, Waka
AU - Ochi, Hidenori
AU - Maekawa, Toshiro
AU - Abe, Hiromi
AU - Tsuge, Masataka
AU - Mitsui, Fukiko
AU - Hiraga, Nobuhiko
AU - Imamura, Michio
AU - Takahashi, Shoichi
AU - Kubo, Michaki
AU - Tsunoda, Tatsuhiko
AU - Nakamura, Yusuke
AU - Kumada, Hiromitsu
AU - Chayama, Kazuaki
N1 - Funding Information:
This work was supported in part by Grants-in-Aid for scientific research and development from the Ministry of Health, Labor and Welfare and the Ministry of Education, Culture, Sports, Science, and Technology, of the Government of Japan . Part of this work was carried out at the Analysis Center of Life Science, Hiroshima University. The authors thank Yasufumi Hayashida, Rie Akiyama, Yoshie Yoshida, Kazuyo Hattori, Mariko Shiota, Hiromi Ishino, and Takako Yokogi for excellent technical assistance, and Yuko Nagai, Junko Sakamiya and Aya Furukawa for clerical assistance.
PY - 2011/3
Y1 - 2011/3
N2 - Background & Aims: Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b. Methods: We analyzed predictive factors for sustained virological response (SVR) in a retrospective study of 719 patients with either genotype 2a (530) or 2b (189). Of these patients, 160 were treated with PEG-RBV and 559 were treated with interferon monotherapy. We evaluated predictive factors including HCV RNA, histological findings, IL28B SNP genotypes (rs8099917, rs12979860, and rs12980275), and the effect of treatment regimen and prior treatment history. Results: HCV RNA viral load, treatment regimen, and rs8099917 genotypes independently contributed to the effect of the therapy. For patients treated with PEG-RBV, rs8099917 and viral load were independent predictive factors for SVR in genotype 2b but not in genotype 2a. Conversely, in patients treated with interferon monotherapy, viral load and rs8099917 were independent predictive factors for SVR in genotype 2a but not in genotype 2b. The favorable rs8099917 genotype is also associated with a steep decline in viral load by the second week of treatment. Conclusions: Initial viral load and rs8099917 genotype are significant independent predictors of SVR in genotype 2 patients.
AB - Background & Aims: Common IL28B locus polymorphisms (SNPs rs8099917 and rs12979860) have been reported to affect peg-interferon plus ribavirin combination therapy (PEG-RBV) for hepatitis C virus (HCV) genotype 1b, but few reports have examined their effect on other two common genotypes, 2a and 2b. Methods: We analyzed predictive factors for sustained virological response (SVR) in a retrospective study of 719 patients with either genotype 2a (530) or 2b (189). Of these patients, 160 were treated with PEG-RBV and 559 were treated with interferon monotherapy. We evaluated predictive factors including HCV RNA, histological findings, IL28B SNP genotypes (rs8099917, rs12979860, and rs12980275), and the effect of treatment regimen and prior treatment history. Results: HCV RNA viral load, treatment regimen, and rs8099917 genotypes independently contributed to the effect of the therapy. For patients treated with PEG-RBV, rs8099917 and viral load were independent predictive factors for SVR in genotype 2b but not in genotype 2a. Conversely, in patients treated with interferon monotherapy, viral load and rs8099917 were independent predictive factors for SVR in genotype 2a but not in genotype 2b. The favorable rs8099917 genotype is also associated with a steep decline in viral load by the second week of treatment. Conclusions: Initial viral load and rs8099917 genotype are significant independent predictors of SVR in genotype 2 patients.
UR - http://www.scopus.com/inward/record.url?scp=79951675730&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=79951675730&partnerID=8YFLogxK
U2 - 10.1016/j.jhep.2010.07.032
DO - 10.1016/j.jhep.2010.07.032
M3 - Article
C2 - 21112660
AN - SCOPUS:79951675730
SN - 0168-8278
VL - 54
SP - 408
EP - 414
JO - Journal of Hepatology
JF - Journal of Hepatology
IS - 3
ER -